Abstract:Prolonged metabolic suppression in the brain is a well-characterized secondary pathology of both experimental and clinical traumatic brain injury (TBI). AMP-activated kinase (AMPK) acts as a cellular energy sensor that, when activated, regulates various metabolic and catabolic pathways to decrease ATP consumption and increase ATP synthesis. As energy availability after TBI is suppressed, we questioned if increasing AMPK activity after TBI would improve cognitive outcome. TBI was delivered using the electromagnetic controlled cortical impact model on male Sprague-Dawley rats (275-300 g) and C57BL/6 mice (20-25 g). AMPK activity within the injured parietal cortex and ipsilateral hippocampus was inferred by western blots using phospho-specific antibodies. The consequences of acute manipulation of AMPK signaling on cognitive function were assessed using the Morris water maze task. We found that AMPK activity is decreased as a result of injury, as indicated by reduced AMPK phosphorylation and corresponding changes in the phosphorylation of its downstream targets: ribosomal protein S6 and Akt Substrate of 160 kDa (AS160). Increasing AMPK activity after injury using the drugs 5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide or metformin did not affect spatial learning, but significantly improved spatial memory. Taken together, our results suggest that decreased AMPK activity after TBI may contribute to the cellular energy crisis in the injured brain, and that AMPK activators may have therapeutic utility. Increased phosphorylation of Thr172 activates AMP-activated protein kinase (AMPK) under conditions of low cellular energy availability. This leads to inhibition of energy consuming, while activating energy generating, processes. Hill et al., present data to indicate that TBI decreases Thr172 phosphorylation and that its stimulation by pharmacological agents offers neuroprotection and improves memory. These results suggest that decreased AMPK phosphorylation after TBI incorrectly signals the injured brain that excess energy is available, thereby contributing to the cellular energy crisis and memory impairments.

AMP-activated protein kinase activators have compound and concentration-specific effects on brain metabolism

AMP‐activated protein kinase (AMPK) regulates astrocyte oxidative metabolism by balancing TCA cycle dynamics

Pharmacological Inhibition of AMP-activated Protein Kinase Provides Neuroprotection in Stroke

A Pharmacological Activator of AMP-Activated Protein Kinase Protects Hypoxic Neurons in a Concentration-Dependent Manner

Brain permeable AMPK activator R481 raises glycemia by autonomic nervous system activation and amplifies the counterregulatory response to hypoglycemia in rats

AMPK-mediated regulation of neuronal metabolism and function in brain diseases

Evaluation of AMPK activity in mice by measuring activator-induced glucose uptake

Structural Determinants For Small-Molecule Activation Of Skeletal Muscle Ampk Alpha 2 Beta 2 Gamma 1 By The Glucose Importagog Sc4

Traumatic brain injury decreases AMP-activated protein kinase activity and pharmacological enhancement of its activity improves cognitive outcome

Role of hindbrain adenosine 5'-monophosphate-activated protein kinase (AMPK) in hypothalamic AMPK and metabolic neuropeptide adaptation to recurring insulin-induced hypoglycemia in the male rat

Participation of Hindbrain AMP-Activated Protein Kinase in Glucoprivic Feeding

Impact of Brain Fatty Acid Signaling on Peripheral Insulin Action in Mice.

The cerebral metabolic effects of manipulating glutamatergic systems within the basal forebrain in conscious rats.

Brain-specific repression of AMPK1 alleviates pathophysiology in Alzheimer's model mice

5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms.

Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.

Protein Expression Alteration In Hippocampus Upon Genetic Repression Of Ampk Alpha Isoforms

Highlighting the protective or degenerative role of AMPK activators in dementia experimental models.

AMP-activated protein kinase: the current landscape for drug development

Identifying New AMP-Activated Protein Kinase Inhibitors That Protect against Ischemic Brain Injury

Potent PDE4 inhibitor activates AMPK and Sirt1 to induce mitochondrial biogenesis